Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Incyte reports positive results from Phase IIa arthritis study
Results from the first of four treatment groups, involving 12 treated and four placebo patients, demonstrated that the 15mg twice-daily dose of INCB18424 was well tolerated and provided
Results from the first of four treatment groups, involving 12 treated and four placebo patients, demonstrated that the 15mg twice-daily dose of INCB18424 was well tolerated and provided
The new facility provides leading capabilities for the formulation of new investigational medicines that have the potential to treat cancer and other deadly diseases. The center’s technology and
Dr Freedman joined Locus in January, 2008 as chief medical officer, and vice president of clinical research and regulatory affairs. Prior to joining Locus, Dr Freedman was at
PharmaForm will develop the drug products to deliver Pear Tree’s confidential drug substances to the vaginal cavity. Stephen Rocamboli, president of Pear Tree Pharmaceuticals, said: “We are pleased
The main goal of this trial is to evaluate the pharmacokinetic, the pharmacodynamic and the safety of Graspa, ERYtech Pharma’s new medicinal product. Approximately 24 patients comprised of
The ‘ZRx Prescriber’ is a Web application that runs on a pocket computer or a personal computer. The tool is used by physicians to fill out prescriptions and
In this six-week, double-blind, parallel group study, patients will be randomized to one of four arms, receiving a low dose or high dose of BL-1020; risperidone, an approved
John Zehner, president and founder of NukeMed and Dose Shield has been named as president and director of Positron Pharmaceuticals. Positron and Positron Pharmaceuticals acquired Dose Shield for
Under the terms of the agreement, Pfizer will pay Pennsylvania School of Medicine $15 million over a three-year period, during which time scientists from Pfizer and Pennsylvania’s School
Final approval of this product is expected upon expiry of patent protection for the brand product in September 2012, as well as any periods of marketing exclusivity that